Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 29, 2018. The document serves as a transaction notification regarding the grant of share options to Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's ShareSave Plan 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific executive compensation transactions rather than a financial performance report.
| Instrument | Transaction Type | Price (GBP) | Total Volume |
|---|---|---|---|
| Ordinary Shares (ISIN: GB0009252882) | Grant of Options | 12.09 | 3,716 |
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It solely reports the initial notification of option grants executed on November 29, 2018, on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the mechanical disclosure of the option grants.
Important Facts for Investors
- Executive Compensation: Options were granted to six senior executives, including CEO Emma Walmsley, President of Global Vaccines Robert Connor, and Company Secretary Victoria Whyte.
- Transaction Details: All grants were made at a price of £12.09 per share under the ShareSave Plan 2018.
- Volume Distribution: Five executives received 744 options each, while President of Global Affairs Peter Thomson received 446 options.
- Regulatory Context: This filing satisfies disclosure requirements under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for a foreign issuer.